Download PDF
Diabetes aktuell 2022; 20(01): 43-50
DOI: 10.1055/a-1754-9194
Schwerpunkt

Management von Diabetespatienten in der COVID-19-Pandemie

Bidirektionale Beziehungen, pathophysiologische Mechanismen und Empfehlungen
Charlotte Steenblock
1   Department of Internal Medicine III, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden
,
Carlotta Hoffmann
1   Department of Internal Medicine III, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden
,
Tilman D. Rachner
1   Department of Internal Medicine III, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden
,
Florian Guggenbichler
1   Department of Internal Medicine III, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden
,
Ermal Tahirukaj
1   Department of Internal Medicine III, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden
,
Sacipi Bejtullah
1   Department of Internal Medicine III, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden
,
Vsevolod A. Zinserling
2   S. P. Botkin Clinical Infectious Diseases Hospital, St. Petersburg (Russland)
3   V. A. Almasov Scientific Research Center, St. Petersburg (Russland)
,
Zsuzanna Varga
4   Department of Pathology and Molecular Pathology, University Hospital Zurich, Zürich (Schweiz)
,
Stefan R. Bornstein
1   Department of Internal Medicine III, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden
4   Department of Pathology and Molecular Pathology, University Hospital Zurich, Zürich (Schweiz)
,
Nikolaos Perakakis
1   Department of Internal Medicine III, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden
5   Paul Langerhans Institute Dresden (PLID), Helmholtz Center Munich, University Hospital and Faculty of Medicine, TU Dresden, Dresden
6   German Center for Diabetes Research (DZD e.V.), Neuherberg
› Author Affiliations
› Further Information
Also available at
    Permissions and Reprints

ZUSAMMENFASSUNG

Über 10 % der deutschen Bevölkerung leiden an metabolischen Krankheiten wie Diabetes, Adipositas, oder nicht alkoholischer Steatohepatitis. Betroffene sind während der COVID-19-Pandemie einem besonderen Risiko ausgesetzt, gibt es doch zahlreiche Hinweise auf eine bidirektionale Beziehung zwischen diesen Krankheiten und COVID-19. Einerseits besteht ein deutlich erhöhtes Risiko für das Auftreten schwerer Krankheitsverläufe bis hin zum Tod, andererseits kann eine COVID-19-Infektion bereits bestehende metabolische Störungen verschlimmern oder neu hervorrufen. Wir werden hier die aktuelle Datenlage bezüglich der pathophysiologischen Mechanismen, die zu dieser bidirektionalen Beziehung führen, zusammenfassen und Empfehlungen für den Umgang mit solchen Patienten während und nach einer Infektion aussprechen.



Publication History

Article published online:
24 February 2022

© 2022. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • Literatur

  • 1 Mahamat-Saleh Y, Fiolet T, Rebeaud ME. et al Diabetes, hypertension, body mass index, smoking and COVID-19-related mortality: a systematic review and meta-analysis of observational studies. BMJ Open 2021; 11: e052777
    CrossrefPubMedGoogle Scholar
  • 2 Heidarpour M, Abhari AP, Sadeghpour N. et al Prediabetes and COVID-19 severity, an underestimated risk factor: A systematic review and meta-analysis. Diabetes Metab Syndr 2021; 15: 102307
    CrossrefPubMedGoogle Scholar
  • 3 Kumar A, Arora A, Sharma P. et al Is diabetes mellitus associated with mortality and severity of COVID-19? A meta-analysis. Diabetes Metab Syndr 2020; 14: 535-545
    CrossrefPubMedGoogle Scholar
  • 4 Sahni S, Gupta G, Sarda R. et al Impact of metabolic and cardiovascular disease on COVID-19 mortality: A systematic review and meta-analysis. Diabetes Metab Syndr 2021; 5: 102308
    CrossrefPubMedGoogle Scholar
  • 5 Kim NH, Kim KJ, Choi J, Kim SG.. Metabolically unhealthy individuals, either with obesity or not, have a higher risk of critical coronavirus disease 2019 outcomes than metabolically healthy individuals without obesity. Metabolism. 2021: 154894
    Google Scholar
  • 6 Xiao F, Zhou YC, Zhang MB. et al Hyperglycemia and blood glucose deterioration are risk factors for severe COVID-19 with diabetes: A two-center cohort study. J Med Virol. 2021
    Google Scholar
  • 7 Eskenazi B, Rauch S, Iurlaro E. et al Diabetes mellitus, maternal adiposity, and insulin-dependent gestational diabetes are associated with Covid-19 in pregnancy: The INTERCOVID Study. Am J Obstet Gynecol. 2021
    Google Scholar
  • 8 Endo K, Miki T, Itoh T. et al Impact of the COVID-19 Pandemic on Glycemic Control and Blood Pressure Control in Patients with Diabetes in Japan. Intern Med 2022; 61: 37-48
    CrossrefPubMedGoogle Scholar
  • 9 Wang W, Chai Z, Cooper ME. et al High Fasting Blood Glucose Level With Unknown Prior History of Diabetes Is Associated With High Risk of Severe Adverse COVID-19 Outcome. Front Endocrinol (Lausanne). 2021; 12: 791476
    CrossrefPubMedGoogle Scholar
  • 10 Kim JS, Lee JY, Yang JW. et al Immunopathogenesis and treatment of cytokine storm in COVID-19. Theranostics 2021; 11: 316-329
    CrossrefPubMedGoogle Scholar
  • 11 Hotamisligil GS. Inflammation, metaflammation and immunometabolic disorders. Nature 2017; 542: 177-185
    CrossrefPubMedGoogle Scholar
  • 12 Berrou J, Fougeray S, Venot M. et al Natural killer cell function, an important target for infection and tumor protection, is impaired in type 2 diabetes. PLoS One 2013; 8: e62418
    CrossrefPubMedGoogle Scholar
  • 13 Xia C, Rao X, Zhong J. Role of T Lymphocytes in Type 2 Diabetes and Diabetes-Associated Inflammation. J Diabetes Res 2017; 2017: 6494795
    PubMedGoogle Scholar
  • 14 Zhou Y, Chi J, Lv W, Wang Y. Obesity and diabetes as high-risk factors for severe coronavirus disease 2019 (Covid-19). Diabetes Metab Res Rev 2021; 37: e3377
    CrossrefPubMedGoogle Scholar
  • 15 Le Goff B, Berthelot JM, Maugars Y, Romas E. Alternative use of bisphosphonate therapy for rheumatic disease. Curr Pharm Des 2010; 16: 3045-3052
    CrossrefPubMedGoogle Scholar
  • 16 Zheng H, Wu J, Jin Z, Yan LJ. Potential Biochemical Mechanisms of Lung Injury in Diabetes. Aging Dis 2017; 8: 7-16
    CrossrefPubMedGoogle Scholar
  • 17 Upadhyay J, Farr O, Perakakis N. et al Obesity as a Disease. Med Clin North Am 2018; 102: 13-33
    CrossrefPubMedGoogle Scholar
  • 18 Kaul K, Tarr JM, Ahmad SI. et al Introduction to diabetes mellitus. Adv Exp Med Biol 2012; 771: 1-11
    Google Scholar
  • 19 Lim S, Bae JH, Kwon HS, Nauck MA. COVID-19 and diabetes mellitus: from pathophysiology to clinical management. Nat Rev Endocrinol 2021; 17: 11-30
    CrossrefPubMedGoogle Scholar
  • 20 Steenblock C, Schwarz PEH, Ludwig B. et al COVID-19 and metabolic disease: mechanisms and clinical management. Lancet Diabetes Endocrinol 2021; 9: 786-798
    CrossrefPubMedGoogle Scholar
  • 21 Thomas MC, Brownlee M. et al Diabetic kidney disease. Nat Rev Dis Primers 2015; 1: 15018
    Google Scholar
  • 22 Menon R, Otto EA, Sealfon R. et al SARS-CoV-2 receptor networks in diabetic and COVID-19-associated kidney disease. Kidney Int 2020; 98: 1502-1518
    CrossrefPubMedGoogle Scholar
  • 23 Diao B, Wang C, Wang R. et al Human kidney is a target for novel severe acute respiratory syndrome coronavirus 2 infection. Nat Commun 2021; 12: 2506
    CrossrefPubMedGoogle Scholar
  • 24 Cheng Y, Luo R, Wang K. et al Kidney disease is associated with in-hospital death of patients with COVID-19. Kidney Int 2020; 97: 829-838
    CrossrefPubMedGoogle Scholar
  • 25 Henry BM, Lippi G. Chronic kidney disease is associated with severe coronavirus disease 2019 (COVID-19) infection. Int Urol Nephrol 2020; 52: 1193-1194
    CrossrefPubMedGoogle Scholar
  • 26 Portoles J, Marques M, Lopez-Sanchez P. et al Chronic kidney disease and acute kidney injury in the COVID-19 Spanish outbreak. Nephrol Dial Transplant 2020; 35: 1353-1361
    CrossrefPubMedGoogle Scholar
  • 27 Carriazo S, Kanbay M, Ortiz A. Kidney disease and electrolytes in COVID-19: more than meets the eye. Clin Kidney J 2020; 13: 274-280
    CrossrefPubMedGoogle Scholar
  • 28 Steenblock C, Richter S, Berger I. et al Viral infiltration of pancreatic islets in patients with COVID-19. Nat Commun 2021; 12: 3534
    CrossrefPubMedGoogle Scholar
  • 29 Maestre-Muniz MM, Arias A, Mata-Vazquez E. et al Long-Term Outcomes of Patients with Coronavirus Disease 2019 at One Year after Hospital Discharge. J Clin Med 2021; 10: 2945
    Google Scholar
  • 30 Kumaran NK, Karmakar BK, Taylor OM. Coronavirus disease-19 (COVID-19) associated with acute necrotising pancreatitis (ANP). BMJ Case Rep 2020; 13: e237903
    CrossrefPubMedGoogle Scholar
  • 31 Ayoubkhani D, Khunti K, Nafilyan V. et al Post-covid syndrome in individuals admitted to hospital with covid-19: retrospective cohort study. BMJ 2021; 372: n693
    CrossrefPubMedGoogle Scholar
  • 32 Al-Aly Z, Xie Y, Bowe B. High-dimensional characterization of post-acute sequelae of COVID-19. Nature 2021; 594: 259-264
    CrossrefPubMedGoogle Scholar
  • 33 Mohammad RA, Nguyen CT, Costello PG. et al Medication Changes and Diagnosis of New Chronic Illnesses in COVID-19 Intensive Care Unit Survivors. Ann Pharmacother. 2022: 1 0600280211063319
    Google Scholar
  • 34 The OpenSAFELY Collaborative Tazare J, Tomlinson L, Hickman G. et al Rates of serious clinical outcomes in survivors of hospitalisation with COVID-19: a descriptive cohort study within the OpenSAFELY platform. 2021
    Google Scholar
  • 35 Barrett CE, Koyama AK, Alvarez P. et al Risk for Newly Diagnosed Diabetes >30 Days After SARS-CoV-2 Infection Among Persons Aged <18 Years – United States, March 1, 2020–June 28, 2021. MMWR Morb Mortal Wkly Rep 2022; 71: 59-65
    CrossrefPubMedGoogle Scholar
  • 36 Unsworth R, Wallace S, Oliver NS. et al New-Onset Type 1 Diabetes in Children During COVID-19: Multicenter Regional Findings in the U.K. Diabetes Care 2020; 43: e170-e171
    CrossrefPubMedGoogle Scholar
  • 37 Vlad A, Serban V, Timar R. et al Increased Incidence of Type 1 Diabetes during the COVID-19 Pandemic in Romanian Children. Medicina (Kaunas) 2021; 57: 973
    CrossrefPubMedGoogle Scholar
  • 38 Kamrath C, Monkemoller K, Biester T. et al Ketoacidosis in Children and Adolescents With Newly Diagnosed Type 1 Diabetes During the COVID-19 Pandemic in Germany. JAMA 2020; 324: 801-804
    CrossrefPubMedGoogle Scholar
  • 39 Delpeut J, Giani E, Louet D. et al Variable incidence of ketoacidosis in youth with type 1 diabetes onset during Covid-19 pandemic peaks in France. Diabetes Metab. 2022: 101322
    Google Scholar
  • 40 Ammar A, Brach M, Trabelsi K. et al Effects of COVID-19 Home Confinement on Eating Behaviour and Physical Activity: Results of the ECLB-COVID19 International Online Survey. Nutrients 2020; 12: 1583
    CrossrefPubMedGoogle Scholar
  • 41 Rowlands AV, Henson JJ, Coull NA. et al The impact of COVID-19 restrictions on accelerometer-assessed physical activity and sleep in individuals with type 2 diabetes. Diabet Med 2021; 38: e14549
    CrossrefPubMedGoogle Scholar
  • 42 Ruissen MM, Regeer H, Landstra CP. et al Increased stress, weight gain and less exercise in relation to glycemic control in people with type 1 and type 2 diabetes during the COVID-19 pandemic. BMJ Open Diabetes Res Care 2021; 9: e002035
    CrossrefPubMedGoogle Scholar
  • 43 Almandoz JP, Xie L, Schellinger JN. et al Impact of COVID-19 stay-at-home orders on weight-related behaviours among patients with obesity. Clin Obes 2020; 10: e12386
    CrossrefPubMedGoogle Scholar
  • 44 Bennett G, Young E, Butler I, Coe S. The Impact of Lockdown During the COVID-19 Outbreak on Dietary Habits in Various Population Groups: A Scoping Review. Front Nutr 2021; 8: 626432
    CrossrefPubMedGoogle Scholar
  • 45 Martinez-Ferran M, de la Guia-Galipienso F, Sanchis-Gomar F, Pareja-Galeano H. Metabolic Impacts of Confinement during the COVID-19 Pandemic Due to Modified Diet and Physical Activity Habits. Nutrients 2020; 12: 1549
    CrossrefPubMedGoogle Scholar
  • 46 Haynes SC, Kompala T, Tancredi DJ. et al Factors Associated With Discontinuation of Subspecialty Diabetes Care During the COVID-19 Pandemic: A Multisite Retrospective Cohort Study. Diabetes Care 2022; 45: e34-e36
    CrossrefPubMedGoogle Scholar
  • 47 Kuehn BM. Younger Adults With Diabetes Miss Care, Disregard COVID-19 Precautions. JAMA 2022; 327: 116
    CrossrefPubMedGoogle Scholar
  • 48 Chudasama YV, Gillies CL, Zaccardi F. et al Impact of COVID-19 on routine care for chronic diseases: A global survey of views from healthcare professionals. Diabetes Metab Syndr 2020; 14: 965-967
    CrossrefPubMedGoogle Scholar
  • 49 Purvis RS, Moore RA, Ayers BL. et al Diabetes Self-Care Behaviors and Barriers to Clinical Care During COVID-19 Pandemic for Marshallese Adults. Sci Diabetes Self Manag Care. 2020 26350106211065390
    Google Scholar
  • 50 Ozdin S, Bayrak Ozdin S. Levels and predictors of anxiety, depression and health anxiety during COVID-19 pandemic in Turkish society: The importance of gender. Int J Soc Psychiatry 2020; 66: 504-511
    CrossrefPubMedGoogle Scholar
  • 51 Hossain MM, Tasnim S, Sultana A. et al Epidemiology of mental health problems in COVID-19: a review. F1000Res 2020; 9: 636
    CrossrefPubMedGoogle Scholar
  • 52 Lei L, Huang X, Zhang S. et al Comparison of Prevalence and Associated Factors of Anxiety and Depression Among People Affected by versus People Unaffected by Quarantine During the COVID-19 Epidemic in Southwestern China. Med Sci Monit 2020; 26: e924609
    PubMedGoogle Scholar
  • 53 Cyranka K, Dudek D, Malecki MT. et al Psychological Crisis Intervention for COVID-19 Lockdown Stress in Patients With Type 1 Diabetes Mellitus: Survey Study and Qualitative Analysis. JMIR Ment Health 2021; 8: e28097
    CrossrefPubMedGoogle Scholar
  • 54 Durmus M, Ciftci N, Gercek A, Durmus Y.. The Effect of COVID -19 Crisis on Hopelessness, Loneliness and Spiritual Well-Being of Patients with Type 1 and Type 2 Diabetes in Turkey. J Relig Health. 2022
    Google Scholar
  • 55 Group RC, Horby P, Lim WS. et al Dexamethasone in Hospitalized Patients with Covid-19. N Engl J Med 2021; 384: 693-704
    CrossrefPubMedGoogle Scholar
  • 56 Group WHOREAfC-TW Sterne JAC, Murthy S, Diaz JV. et al Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19: A Meta-analysis. JAMA 2020; 324: 1330-1341
    CrossrefPubMedGoogle Scholar
  • 57 Perez A, Jansen-Chaparro S, Saigi I. et al Glucocorticoid-induced hyperglycemia. J Diabetes 2014; 6: 9-20
    CrossrefPubMedGoogle Scholar
  • 58 Santos A, Magro DO, Evangelista-Poderoso R, Saad MJA. Diabetes, obesity, and insulin resistance in COVID-19: molecular interrelationship and therapeutic implications. Diabetol Metab Syndr 2021; 13: 23
    CrossrefPubMedGoogle Scholar
  • 59 Kow CS, Hasan SS. Mortality risk with preadmission metformin use in patients with COVID-19 and diabetes: A meta-analysis. J Med Virol 2021; 93: 695-697
    CrossrefPubMedGoogle Scholar
  • 60 Scheen AJ. Metformin and COVID-19: From cellular mechanisms to reduced mortality. Diabetes Metab 2020; 46: 423-426
    CrossrefPubMedGoogle Scholar
  • 61 Cheng X, Liu YM, Li H. et al Metformin Is Associated with Higher Incidence of Acidosis, but Not Mortality, in Individuals with COVID-19 and Pre-existing Type 2 Diabetes. Cell Metab 2020; 32: 537-47 e3
    CrossrefPubMedGoogle Scholar
  • 62 Ojeda-Fernandez L, Foresta A, Macaluso G. et al Metformin use is associated with a decrease in risk of hospitalization and mortality in COVID-19 diabetic patients: a population-based study in Lombardy. Diabetes Obes Metab. 2022
    Google Scholar
  • 63 Khunti K, Knighton P, Zaccardi F. et al Prescription of glucose-lowering therapies and risk of COVID-19 mortality in people with type 2 diabetes: a nationwide observational study in England. Lancet Diabetes Endocrinol 2021; 9: 293-303
    CrossrefPubMedGoogle Scholar
  • 64 Kosiborod MN, Esterline R, Furtado RHM. et al Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol 2021; 9: 586-594
    CrossrefPubMedGoogle Scholar
  • 65 Katsiki N, Ferrannini E. Anti-inflammatory properties of antidiabetic drugs: A “promised land” in the COVID-19 era?. J Diabetes Complications 2020; 34: 107723
    CrossrefPubMedGoogle Scholar
  • 66 Nohara H, Nakashima R, Kamei S. et al Intratracheal GLP-1 receptor agonist treatment up-regulates mucin via p38 and exacerbates emphysematous phenotype in mucus hypersecretory obstructive lung diseases. Biochem Biophys Res Commun 2020; 524: 332-339
    CrossrefPubMedGoogle Scholar
  • 67 Bouhanick B, Cracowski JL, Faillie JL. DPP-4 inhibitors and severe course of illness in patients with COVID-19. Therapie 2021; 76: 359-360
    CrossrefPubMedGoogle Scholar
  • 68 Noh Y, Oh IS, Jeong HE. et al Association Between DPP-4 Inhibitors and COVID-19-Related Outcomes Among Patients With Type 2 Diabetes. Diabetes Care 2021; 44: e64-e66
    CrossrefPubMedGoogle Scholar
  • 69 Rhee SY, Lee J, Nam H. et al Effects of a DPP-4 Inhibitor and RAS Blockade on Clinical Outcomes of Patients with Diabetes and COVID-19. Diabetes Metab J 2021; 45: 251-259
    CrossrefPubMedGoogle Scholar
  • 70 Pal R, Banerjee M, Mukherjee S. et al Dipeptidyl peptidase-4 inhibitor use and mortality in COVID-19 patients with diabetes mellitus: an updated systematic review and meta-analysis. Ther Adv Endocrinol Metab. 2021 12. 2042018821996482
    Google Scholar
  • 71 Solerte SB, D’Addio F, Trevisan R. et al Sitagliptin Treatment at the Time of Hospitalization Was Associated With Reduced Mortality in Patients With Type 2 Diabetes and COVID-19: A Multicenter, Case-Control, Retrospective, Observational Study. Diabetes Care 2020; 43: 2999-3006
    CrossrefPubMedGoogle Scholar
  • 72 Dandona P, Ghanim H. Diabetes, Obesity, COVID-19, Insulin, and Other Antidiabetes Drugs. Diabetes Care 2021; 44: 1929-1933
    CrossrefPubMedGoogle Scholar
  • 73 Yu B, Li C, Sun Y, Wang DW. Insulin Treatment Is Associated with Increased Mortality in Patients with COVID-19 and Type 2 Diabetes. Cell Metab 2021; 33: 65-77 e2
    CrossrefPubMedGoogle Scholar
  • 74 Sourij C, Tripolt NJ, Aziz F. et al Humoral immune response to Covid-19 vaccination in diabetes: age-dependent but independent of type of diabetes and glycaemic control – the prospective COVAC-DM cohort study. Diabetes Obes Metab. 2022
    Google Scholar
  • 75 Pal R, Bhadada SK, Misra A. COVID-19 vaccination in patients with diabetes mellitus: Current concepts, uncertainties and challenges. Diabetes Metab Syndr 2021; 15: 505-508
    CrossrefPubMedGoogle Scholar
  • 76 McGovern AP, Thomas NJ, Vollmer SJ. et al The disproportionate excess mortality risk of COVID-19 in younger people with diabetes warrants vaccination prioritisation. Diabetologia 2021; 64: 1184-1186
    CrossrefPubMedGoogle Scholar
  • 77 Petrie JR, Boyle JG, Ali K. et al A post COVID-19 ‘Marshall Plan’ for type 2 diabetes. Diabet Med 2021; 38: e14439
    CrossrefPubMedGoogle Scholar
  • 78 Saiyed S, Joshi R, Khattab S, Dhillon S. The Rapid Implementation of an Innovative Virtual Diabetes Boot Camp Program: Case Study. JMIR Diabetes 2022; 7: e32369
    CrossrefPubMedGoogle Scholar
  • 79 Hamrouni M, Roberts MJ, Thackray A. et al Associations of obesity, physical activity level, inflammation and cardiometabolic health with COVID-19 mortality: a prospective analysis of the UK Biobank cohort. BMJ Open 2021; 11: e055003
    CrossrefPubMedGoogle Scholar
  • 80 Sallis R, Young DR, Tartof SY. et al Physical inactivity is associated with a higher risk for severe COVID-19 outcomes: a study in 48 440 adult patients. Br J Sports Med 2021; 55: 1099-1105
    CrossrefPubMedGoogle Scholar
  • 81 Ruberti OM, Telles GD, Rodrigues B. Stress and Physical Inactivity: Two Explosive Ingredients for the Heart in COVID-19 Pandemic Times. Curr Cardiol Rev 2021; 17: 6-14
    CrossrefPubMedGoogle Scholar
  • 82 Raveendran AV, Misra A. Post COVID-19 Syndrome (“Long COVID”) and Diabetes: Challenges in Diagnosis and Management. Diabetes Metab Syndr 2021; 15: 102235
    CrossrefPubMedGoogle Scholar
  • 83 Sudre CH, Murray B, Varsavsky T. et al Attributes and predictors of long COVID. Nat Med 2021; 27: 626-631
    CrossrefPubMedGoogle Scholar
  • 84 Fernandez-de-Las-Penas C, Guijarro C, Torres-Macho J. et al Diabetes and the Risk of Long-term Post-COVID Symptoms. Diabetes 2021; 70: 2917-2921
    CrossrefPubMedGoogle Scholar
  • 85 Nalbandian A, Sehgal K, Gupta A. et al Post-acute COVID-19 syndrome. Nat Med 2021; 27: 601-615
    CrossrefPubMedGoogle Scholar
  • 86 Montefusco L, Ben Nasr M, D’Addio F. et al Acute and long-term disruption of glycometabolic control after SARS-CoV-2 infection. Nat Metab 2021; 3: 774-785
    Google Scholar
  • 87 Unnikrishnan R, Misra A. Diabetes and COVID19: a bidirectional relationship. Nutr Diabetes 2021; 11: 21
    CrossrefPubMedGoogle Scholar
  • 88 Ramakrishnan RK, Kashour T, Hamid Q. et al Unraveling the Mystery Surrounding Post-Acute Sequelae of COVID-19. Front Immunol 2021; 12: 686029
    CrossrefPubMedGoogle Scholar
  • 89 Yan Z, Yang M, Lai CL. Long COVID-19 Syndrome: A Comprehensive Review of Its Effect on Various Organ Systems and Recommendation on Rehabilitation Plans. Biomedicines 2021; 9: 966
    CrossrefPubMedGoogle Scholar